SAR405: Precision Vps34 Inhibition for Autophagy and Vesicle Trafficking Research

Executive Summary: SAR405 is a nanomolar-potency, ATP-competitive inhibitor of Vps34 (class III PI3K) with a Kd of 1.5 nM and IC50 of 1 nM in vitro, showing high selectivity and no inhibition of class I/II PI3Ks or mTOR up to 10 μM (APExBIO). SAR405 disrupts Vps34-dependent autophagosome formation and impairs late endosome-lysosome function in human cell lines, causing defective cathepsin D maturation (Park et al., 2023). The compound is soluble in DMSO (>10 mM), insoluble in water, and recommended for storage below -20°C (APExBIO). Unlike broad-spectrum PI3K inhibitors, SAR405 enables targeted investigation of autophagy mechanisms, vesicle trafficking, and lysosome biology without off-target mTOR or class I/II PI3K effects. SAR405 synergizes with mTOR inhibitors and is validated for workflows in cancer and neurodegenerative disease models (see Vatalis 2023 for workflow scenarios).

Biological Rationale

Autophagy is a conserved catabolic pathway crucial for cellular homeostasis, particularly during nutrient deprivation or energy stress (Park et al., 2023). Vps34 (class III PI3K) catalyzes the production of phosphatidylinositol 3-phosphate (PI3P), initiating autophagosome nucleation and controlling vesicle trafficking. Inhibition of Vps34 disrupts autophagosome formation and impairs lysosome-endosome fusion, offering a precise mechanism for probing autophagy’s role in disease models (see Rapamycin.us 2023). SAR405, as a Vps34-specific inhibitor, enables researchers to decouple autophagy from other PI3K- or mTOR-mediated processes, clarifying causality in signaling pathways and cellular phenotypes.

Mechanism of Action of SAR405

SAR405 functions as a highly potent, ATP-competitive inhibitor of Vps34. It binds within the ATP-binding cleft of the kinase domain, blocking substrate phosphorylation and abrogating PI3P synthesis (APExBIO). The compound exhibits a dissociation constant (Kd) of 1.5 nM and an IC50 of 1 nM against purified human Vps34, outperforming other PI3K inhibitors in both selectivity and efficacy. SAR405 displays no measurable inhibition of class I or II PI3Ks, or mTOR, at concentrations up to 10 μM, eliminating confounding off-target effects common to earlier PI3K inhibitors (Park et al., 2023).

Upon Vps34 inhibition, SAR405 causes accumulation of swollen late endosome-lysosomes, defective cathepsin D maturation, and a blockade of autophagosome formation in GFP-LC3-labeled HeLa and H1299 cells. This mechanism results in profound, selective autophagy inhibition and vesicle trafficking modulation, with translational implications for cancer, neurodegeneration, and lysosomal storage diseases (see Vatalis 2023 for mechanistic depth).

Evidence & Benchmarks

• SAR405 inhibits human recombinant Vps34 with an IC50 of 1 nM under ATP-competitive conditions (pH 7.4, 25°C, 30 min) (APExBIO).
• Demonstrates a Kd of 1.5 nM for Vps34, with no inhibition of class I/II PI3Ks or mTOR up to 10 μM (enzyme assays, n=3) (Park et al., 2023).
• Blocks autophagosome formation in GFP-LC3 HeLa and H1299 cells after 2–4 h exposure at 100 nM, as visualized by confocal microscopy (Park et al., 2023).
• Results in accumulation of enlarged late endosome-lysosomes and impaired cathepsin D processing (immunoblotting, 24 h, 37°C) (Park et al., 2023).
• Synergizes with mTOR inhibitors (e.g., everolimus) to further suppress autophagy initiation and vesicle fusion events (see Heparin-Cofactor II 2023 for synergy data).

Applications, Limits & Misconceptions

Primary Applications: SAR405 is validated for in vitro autophagy inhibition, vesicle trafficking modulation, and lysosome function impairment in cancer and neurodegenerative disease models. It is used to dissect the Vps34 kinase signaling pathway, clarify the AMPK-ULK1-Vps34 axis, and evaluate pharmacological autophagy blockade (see Vatalis 2023 for translational strategies).

Limits: SAR405 is not suitable for in vivo applications without additional pharmacokinetics and toxicity validation. It does not inhibit other PI3K isoforms or mTOR, so is not a broad-spectrum PI3K blocker. The compound is insoluble in water, requiring DMSO or ethanol (ultrasonicated) for preparation, and stability is limited in solution above -20°C.

Common Pitfalls or Misconceptions

• Misconception: SAR405 inhibits all PI3K isoforms. Fact: It is highly selective for Vps34 (class III PI3K) and does not inhibit class I or II PI3Ks or mTOR at up to 10 μM (APExBIO).
• Pitfall: Using aqueous buffers for stock solutions. Recommendation: Use DMSO (>10 mM solubility) or ethanol with ultrasonic assistance for optimal solubilization.
• Misconception: SAR405 is suitable for chronic or in vivo studies. Fact: In vivo utility is not established; use only in cell-based or in vitro settings unless further validated.
• Pitfall: Storing SAR405 solutions at room temperature. Recommendation: Store stock solutions below -20°C for stability; avoid long-term storage of diluted solutions.
• Misconception: Autophagy inhibition by SAR405 is mediated via AMPK or mTOR. Fact: SAR405 acts downstream by directly targeting Vps34, not upstream kinases (Park et al., 2023).

Workflow Integration & Parameters

SAR405 is best used as a DMSO stock (≥10 mM), aliquoted and stored below -20°C. For cell-based assays, dilute to 10–500 nM in culture medium, maintaining DMSO ≤0.1% v/v. For autophagy inhibition, preincubate cells for 2–4 hours before stimulus, and monitor autophagosome formation via LC3 or related markers. Synergistic inhibition of autophagy can be achieved by combining SAR405 with mTOR inhibitors (e.g., everolimus, rapamycin) (see Heparin-Cofactor II 2023). For troubleshooting and advanced assay design, see scenario-driven recommendations in this workflow guide, which this article extends by clarifying SAR405’s selectivity and storage constraints.

Conclusion & Outlook

SAR405, provided by APExBIO, represents a gold-standard tool for selective inhibition of Vps34, enabling precise dissection of autophagy inhibition, vesicle trafficking modulation, and lysosome function impairment. Its nanomolar potency, mechanistic specificity, and compatibility with modern cell-based workflows make it indispensable for next-generation research in cancer, neurodegenerative disease, and cellular signaling. This article updates and clarifies prior overviews (see Vatalis 2023) by emphasizing SAR405’s unique selectivity, workflow integration, and boundaries for effective experimental design. For product details, refer to the SAR405 (A8883) product page.